Aerie Pharmaceuticals Revenue and Competitors

Claim your profile

Location

$993.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aerie Pharmaceuticals's estimated annual revenue is currently $24.2M per year.(i)
  • Aerie Pharmaceuticals received $86.2M in venture funding in January 2018.
  • Aerie Pharmaceuticals's estimated revenue per employee is $64,828
  • Aerie Pharmaceuticals's total funding is $993.1M.

Employee Data

  • Aerie Pharmaceuticals has 373 Employees.(i)
  • Aerie Pharmaceuticals grew their employee count by -1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.2M160%N/AN/A
#2
$67.1M3346%N/AN/A
#3
$25.5M12755%N/AN/A
#4
$72.6M28928%$35MN/A
#5
$3.3M4048%N/AN/A
#6
$3.1M38-25%N/AN/A
#7
$165.7M21614%$250.7MN/A
#8
$22.3M1114%$637.8KN/A
#9
$44M2198%N/AN/A
#10
$7124.6M35446N/AN/AN/A

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care. Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye. See the future of eye care with Aerie.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$993.1M

Total Funding

373

Number of Employees

$24.2M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aerie Pharmaceuticals News

2022-04-20 - Glaucoma Therapeutics Market Size And Forecast | Inotek ...

Inotek Pharmaceuticals, Aerie pharmaceuticals Inc, Teva Pharmaceutical Industry, Bausch & Lomb Incorporated, Allergan plc, Novartis AG,...

2022-04-13 - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to ...

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for...

2022-03-22 - Aerie Pharmaceuticals CEO discusses what's new in the ...

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for...

2019-09-08 - Durham-based Aerie Pharmaceuticals looks to raise $275M

DURHAM — Aerie Pharmaceuticals, a developer of therapies for eye diseases, has launched an offering of $250 million of convertible senior ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.9M37521%N/A
#2
$129.3M38323%N/A
#3
$130.6M387-4%N/A
#4
$87.1M38722%N/A
#5
$35M38917%N/A

Aerie Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2005-10-13$21.0MAAlta Partners, Texas Pacific Group VenturesArticle
2011-03-08$30.0MBClarus Ventures, Sofinnova VenturesArticle
2013-10-28$67.0MUndisclosedRBC Capital MarketsArticle
2014-09-10$125.0MUndisclosedDeerfield Management CompanyArticle
2016-09-19$125.0MUndisclosedCantor Fitzgerald & CoArticle
2017-05-26$50.0MUndisclosedCantor Fitzgerald & Co.Article
2018-01-25$86.2MUndisclosedCantor Fitzgerald & CoArticle